BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

913 related articles for article (PubMed ID: 26392326)

  • 21. Oral Anticoagulation in Asian Patients With Atrial Fibrillation and a History of Intracranial Hemorrhage.
    Lee SR; Choi EK; Kwon S; Jung JH; Han KD; Cha MJ; Oh S; Lip GYH
    Stroke; 2020 Feb; 51(2):416-423. PubMed ID: 31813363
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Time-in-therapeutic-range defined warfarin and direct oral anticoagulants in atrial fibrillation: a Nationwide Cohort Study.
    Lehto M; Luojus A; Halminen O; Haukka J; Putaala J; Linna M; Mustonen P; Kinnunen J; Lehtonen O; Teppo K; Tiili P; Kouki E; Itäinen-Strömberg S; Niemi M; Aro AL; Hartikainen J; Airaksinen KEJ;
    Ann Med; 2024 Dec; 56(1):2364825. PubMed ID: 38873855
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stroke and bleeding risk co-distribution in real-world patients with atrial fibrillation: the Euro Heart Survey.
    Marcucci M; Lip GY; Nieuwlaat R; Pisters R; Crijns HJ; Iorio A
    Am J Med; 2014 Oct; 127(10):979-986.e2. PubMed ID: 24838192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.
    Villines TC; Schnee J; Fraeman K; Siu K; Reynolds MW; Collins J; Schwartzman E
    Thromb Haemost; 2015 Nov; 114(6):1290-8. PubMed ID: 26446456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dabigatran use in elderly patients with atrial fibrillation.
    Avgil-Tsadok M; Jackevicius CA; Essebag V; Eisenberg MJ; Rahme E; Behlouli H; Pilote L
    Thromb Haemost; 2016 Jan; 115(1):152-60. PubMed ID: 26354766
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the CHA
    Yao X; Gersh BJ; Sangaralingham LR; Kent DM; Shah ND; Abraham NS; Noseworthy PA
    Am J Cardiol; 2017 Nov; 120(9):1549-1556. PubMed ID: 28844514
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population.
    Brunetti L; Chen C; White J
    Consult Pharm; 2014 Mar; 29(3):169-78. PubMed ID: 24589766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study.
    Jacobs LG; Billett HH; Freeman K; Dinglas C; Jumaquio L
    Am J Geriatr Pharmacother; 2009 Jun; 7(3):159-66. PubMed ID: 19616184
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predicting Major Bleeding in Ischemic Stroke Patients With Atrial Fibrillation.
    Hilkens NA; Algra A; Greving JP
    Stroke; 2017 Nov; 48(11):3142-3144. PubMed ID: 28931618
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anticoagulation Control in Warfarin-Treated Patients Undergoing Cardioversion of Atrial Fibrillation (from the Edoxaban Versus Enoxaparin-Warfarin in Patients Undergoing Cardioversion of Atrial Fibrillation Trial).
    Lip GYH; Al-Saady N; Jin J; Sun M; Melino M; Winters SM; Zamoryakhin D; Goette A
    Am J Cardiol; 2017 Sep; 120(5):792-796. PubMed ID: 28709650
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Persistence and outcomes of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation.
    Wu S; Xie S; Xu Y; Que D; Yau TO; Wang L; Huang Y
    J Clin Nurs; 2019 May; 28(9-10):1839-1846. PubMed ID: 30667111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of suboptimal anticoagulation treatment with antiplatelet therapy and warfarin on clinical outcomes in patients with nonvalvular atrial fibrillation: A population-wide cohort study.
    Chan EW; Lau WC; Siu CW; Lip GY; Leung WK; Anand S; Man KK; Wong IC
    Heart Rhythm; 2016 Aug; 13(8):1581-8. PubMed ID: 27033342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost efficiency of anticoagulation with warfarin to prevent stroke in medicare beneficiaries with nonvalvular atrial fibrillation.
    Mercaldi CJ; Ciarametaro M; Hahn B; Chalissery G; Reynolds MW; Sander SD; Samsa GP; Matchar DB
    Stroke; 2011 Jan; 42(1):112-8. PubMed ID: 21148442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prescription Patterns and Outcomes of Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulants and Warfarin: A Real-World Analysis.
    Kattoor AJ; Pothineni NV; Goel A; Syed M; Syed S; Paydak H; Mehta JL
    J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):428-434. PubMed ID: 31035795
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dabigatran Versus Warfarin for Atrial Fibrillation in Real-World Clinical Practice: A Systematic Review and Meta-Analysis.
    Romanelli RJ; Nolting L; Dolginsky M; Kym E; Orrico KB
    Circ Cardiovasc Qual Outcomes; 2016 Mar; 9(2):126-34. PubMed ID: 26812933
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan: the SAMURAI-NVAF study.
    Toyoda K; Arihiro S; Todo K; Yamagami H; Kimura K; Furui E; Terasaki T; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Kameda T; Nagakane Y; Hasegawa Y; Mochizuki H; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Kario K; Sato S; Koga M;
    Int J Stroke; 2015 Aug; 10(6):836-42. PubMed ID: 25581108
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes Associated With Resuming Warfarin Treatment After Hemorrhagic Stroke or Traumatic Intracranial Hemorrhage in Patients With Atrial Fibrillation.
    Nielsen PB; Larsen TB; Skjøth F; Lip GY
    JAMA Intern Med; 2017 Apr; 177(4):563-570. PubMed ID: 28241151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation.
    Björck F; Renlund H; Lip GY; Wester P; Svensson PJ; Själander A
    JAMA Cardiol; 2016 May; 1(2):172-80. PubMed ID: 27437888
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation.
    Hankey GJ; Stevens SR; Piccini JP; Lokhnygina Y; Mahaffey KW; Halperin JL; Patel MR; Breithardt G; Singer DE; Becker RC; Berkowitz SD; Paolini JF; Nessel CC; Hacke W; Fox KA; Califf RM;
    Stroke; 2014 May; 45(5):1304-12. PubMed ID: 24743444
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.